Home 2017-10-06T21:08:18+00:00
The Personalis Mission
Our mission is to help cancer patients by enabling the next-generation of immuno-oncology therapeutics and diagnostics through rigorous innovation.

It Starts with Comprehensive Tumor Immunogenomics

Personalis is partnering with biopharma to develop and commercialize the next generation of immuno-oncology therapeutics and diagnostics by providing high-accuracy, validated genomic sequencing and immuno-oncology-focused analytics.
We are a full business partner from early development, through clinical trials and commercialization, through scale-up of products after approval.

Solutions for Personalized
Cancer Vaccines

Solutions for
Biomarker Discovery

A Universal Biomarker Platform for Immuno-Oncology

ACE ImmunoID is designed to harmonize biomarker strategies across clinical and biomarker discovery programs. The platform combines our augmented exome and transcriptome assays with advanced analytics to provide a more complete, multidimensional view of the following key immuno-oncology areas:
Tumor Neoantigens

Identify neoantigens to develop
personalized cancer treatment vaccines

Tumor Microenvironment

Understand the drivers of
immune response

Tumor Escape & Modulators

Elucidate mechanisms of
immune evasion

The ACE Advantage
ACE (Accuracy and Content Enhanced) Technology forms the basis of all Personalis platforms.  ACE improves processes from nucleic acid preparation, to sequencing, to analytics.
Learn More

Nucleic Acid Extraction

Personalis has developed protocols to overcome the challenges of working with difficult samples including FFPE.

Sequencing

Gaps or inconsistent coverage can result in missed content. Personalis ACE Technology augments sequencing gaps for more complete coverage.

Alignment and Variant Discovery

Our state-of-the-art bioinformatics pipelines are optimized for accuracy and performance, resulting in superior sequence alignments and variant calls, including improved SNV and indel detection.

Variant Annotation

We’ve implemented comprehensive annotation to overcome mapping/nomenclature issues, and errors and inconsistencies in database curation.

Analytics

Data is delivered with convenient QC reports and in easy to use formats such as our Neoantigen Discovery Report and our Immunogenomics Report.
Personalis in the News: Personalis Inc. Orders Ten lllumina NovaSeq'” 6000 Systems

READY TO ACCELERATE YOUR IMMUNO-ONCOLOGY STRATEGY?

Contact Us